cIAP Pan-specific Antibody [B1J9]

Catalog No.: F6710

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:2000
    Application
    WB
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human, Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    68 kDa 80 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    cIAP Pan-specific Antibody [B1J9] detects endogenous levels of total cIAP Pan-specific protein.
    Clone
    B1J9
    Synonym(s)
    Cellular inhibitor of apoptosis 2 (C-IAP2), IAP homolog C, hIAP-1; hIAP1, RING finger protein 49, BIRC3, API2, MIHC, RNF49
    Background
    cIAP1 and cIAP2 are closely related inhibitor of apoptosis family members with N‑terminal tandem baculoviral IAP repeat domains, a central caspase‑recruitment domain, and a C‑terminal RING finger that confers ubiquitin E3 ligase activity, positioning them as scaffold enzymes at TNF receptor–associated signaling complexes and other receptor platforms. The BIR domains bind caspases and other signaling proteins, but sequence analyses and mutagenesis show that cIAP BIRs have substitutions in key residues required for tight caspase inhibition, so their primary biochemical activity arises from RING‑dependent ubiquitination rather than potent direct caspase blockade. The RING domain dimerizes and interacts with ubiquitin‑charged E2 enzymes, catalyzing K63 and other polyubiquitin chains on substrates such as RIP1 at the TNF receptor 1 complex, which creates docking sites for TAK1, IKK, and other NF‑κB pathway components and supports prosurvival and proinflammatory transcriptional responses after TNFα stimulation. Either cIAP1 or cIAP2 is sufficient to maintain RIP1 polyubiquitination and NF‑κB activation upon TNFα treatment, and genetic loss of both proteins leads to reduced RIP1 ubiquitination, diminished NF‑κB signaling, and increased formation of RIP1–FADD–caspase‑8 complexes that execute apoptosis. cIAPs also autoubiquitinate and ubiquitinate other adaptors in TNF and related pathways, contributing to turnover of components and to the balance between survival signaling and cell death complexes in response to cytokine and pattern‑recognition receptor inputs. Mitochondria‑derived Smac/DIABLO and HtrA2/Omi bind the BIR domains through IAP‑binding motifs and promote RING‑dependent autoubiquitination and proteasomal degradation of cIAP1 and cIAP2, which lowers cellular cIAP levels and shifts signaling from NF‑κB activation toward caspase‑8 activation and apoptosis in death receptor pathways. Small‑molecule Smac mimetics bind cIAP BIRs, relieve intramolecular inhibition of the RING domain, induce rapid RING‑mediated autoubiquitination, and trigger proteasomal clearance of cIAP1 and, to a lesser extent, cIAP2, providing a tool to experimentally deplete cIAPs and study the resulting switch from prosurvival to proapoptotic signaling. Elevated cIAP1 and cIAP2 expression is reported in multiple cancers, and their E3 ligase activity toward RIP1 and other targets has been linked to maintenance of constitutive NF‑κB activity and survival of malignant cells under stress, while pharmacologic or genetic disruption of cIAP function sensitizes tumor cells to TNF family ligands and chemotherapeutic agents.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください